InVitro International
InVitro International
Your view on IVRO
Overview
What the company does, where it operates, and who runs it.
About InVitro International
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- W. Richard Ulmer
- Headquarters
- 330 East Orangethorpe Avenue, Placentia, CA, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- W. Richard Ulmer
- Headquarters
- 330 East Orangethorpe Avenue, Placentia, CA, US
InVitro International develops test kits for non-animal testing in the United States and internationally.
Its products include Irritection Assay System, an invitro test, which could be used to detect, rank, and predict the ocular and/or dermal irritation potential of cosmetics, consumer products, pharmaceuticals, and chemical raw materials; and Corrositex, an invitro test that determines chemical corrosivity.
The company also provides customized technology services for Irritection Assay System installation and testing process, as well as independent testing laboratory services for irritancy and corrosivity testing requirements.
Its products are principally used by the manufacturers of surfactants, petrochemicals, cosmetics, textiles, paper and pulp, pharmaceuticals, films and resins, solvents and cleaners, and other chemical raw materials. The company was founded in 1985 and is headquartered in Placentia, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for InVitro International, and the rating behind it. IVRO last traded at $0.08, 20.0× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for InVitro International. Starting points for InVitro International: P/E 20.0, beta -0.82 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for InVitro International. InVitro International does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for InVitro International. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for InVitro International. InVitro International has reported as a listed company since 1991. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
InVitro International valued side by side against its closest peers. InVitro International is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold InVitro International, and how their positions are changing. At a $1.8M market value, institutional positions materially move InVitro International's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by InVitro International executives and directors. Shares of InVitro International have traded between $0.06 and $0.16 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming InVitro International. InVitro International is a $1.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming InVitro International. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for InVitro International. Coverage tracks InVitro International within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.